Super-enhancer inhibitors THZ2 and JQ1 reverse temozolomide resistance in glioblastoma by suppressing SE-driven SOX9 expression

Abstract

Aim: Glioblastoma (GBM) is the most malignant grade of glioma, characterized by high recurrence, poor prognosis, and frequent chemoresistance. There is an urgent need for alternative treatment strategies. In this study, we evaluated the effects of THZ2, a covalent inhibitor targeting the super-enhancer (SE) component CDK7, on GBM growth and chemoresistance. We also used another SE inhibitor, JQ1, to further validate the inhibitory effects of targeting SEs in GBM, thereby providing new treatment strategies for patients.

Methods: A variety of in vitro and in vivo assays were performed to explore the anti-GBM effects of SE inhibitors. We assessed the effects of SE inhibitors in combination with temozolomide (TMZ) on GBM cells and calculated the combination index. Additionally, CUT&RUN assays were conducted to examine protein-DNA interactions.

Results: THZ2 inhibited the proliferation, migration, and invasion of GBM cells and induced cell cycle arrest and apoptosis. Furthermore, both THZ2 and JQ1 exhibited synergistic antitumor effects when combined with TMZ in GBM cells. Notably, THZ2 reversed TMZ resistance in GBM cells by suppressing the expression of the SE-associated gene SOX9. We also found that SOX9, CDK7, and BRD4 interact with histone H3K27ac.

Conclusion: Our findings demonstrate that SE inhibitors exert antitumor effects in GBM and act synergistically with TMZ. THZ2 may enhance chemosensitivity by downregulating the SE-related gene SOX9, and it holds promise as a novel therapeutic agent for GBM patients.

Keywords

Glioblastoma / chemoresistance / super-enhancer / CDK7 inhibitor / SOX9

References

[1] Ostrom QT,Neff C.CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019.Neuro Oncol2022;24:v1-95 PMCID:PMC9533228

[2] Weller M,Preusser M.EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.Nat Rev Clin Oncol2021;18:170-86 PMCID:PMC7904519

[3] Messaoudi K,Lagarce F.Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.Drug Discov Today2015;20:899-905

[4] Weller M, van den Bent M, Tonn JC, et al; European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18:e315-29.

[5] Pouyan A,Eslami M.Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.Mol Cancer2025;24:58 PMCID:PMC11863469

[6] Sun X,Lu B.BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network.Nature2023;613:195-202 PMCID:PMC10189659

[7] Kribelbauer-Swietek JF,Gardeux V.Context transcription factors establish cooperative environments and mediate enhancer communication.Nat Genet2024;56:2199-212 PMCID:PMC11525195

[8] Qian H,Tan X,Liu X.Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets.Cell Death Discov2023;9:470 PMCID:PMC10746725

[9] Leeman-Neill RJ,Bizarro J.Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression.Nat Genet2023;55:2160-74 PMCID:PMC10703697

[10] Hamamoto R,Shinkai N.Analysis of super-enhancer using machine learning and its application to medical biology.Brief Bioinform2023;24:bbad107 PMCID:PMC10199775

[11] Chen Y,Ma W.Targeting the epigenetic reader ENL inhibits super-enhancer-driven oncogenic transcription and synergizes with BET inhibition to suppress tumor progression.Cancer Res2024;84:1237-51

[12] Ye J,Feng Y.Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer.Signal Transduct Target Ther2023;8:303 PMCID:PMC10427640

[13] Luo S,Wang Z.Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma.Cancer Lett2024;589:216811

[14] Cai H,Jiang Y.KLF7 regulates super-enhancer-driven IGF2BP2 overexpression to promote the progression of head and neck squamous cell carcinoma.J Exp Clin Cancer Res2024;43:69 PMCID:PMC10913600

[15] Li GH,Qi TT.Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance.J Exp Clin Cancer Res2021;40:174 PMCID:PMC8132395

[16] Lu B,He J.Epigenetic profiling identifies LIF as a super-enhancer-controlled regulator of stem cell-like properties in osteosarcoma.Mol Cancer Res2020;18:57-67

[17] Chen KY,Klein RH.Reciprocal H3.3 gene editing identifies K27M and G34R mechanisms in pediatric glioma including NOTCH signaling.Commun Biol2020;3:363 PMCID:PMC7347881

[18] Meng W,Wang B.CDK7 inhibition is a novel therapeutic strategy against GBM both in vitro and in vivo.Cancer Manag Res2018;10:5747-58 PMCID:PMC6245350

[19] Belew MD,Cheng Z.Emerging roles of cyclin-dependent kinase 7 in health and diseases.Trends Mol Med2025;31:138-51 PMCID:PMC11825286

[20] Jones T,Luyties O.TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network.Sci Adv2025;11:eadr9660 PMCID:PMC11870056

[21] Sun J,Sun X,Gao X.THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.Cell Commun Signal2022;20:138 PMCID:PMC9454178

[22] Chen Z,Chen X.Super-enhancer-driven lncRNA LIMD1-AS1 activated by CDK7 promotes glioma progression.Cell Death Dis2023;14:383 PMCID:PMC10310775

[23] Li B,Fan Y.Therapeutic rationale to target highly expressed CDK7 conferring poor outcomes in triple-negative breast cancer.Cancer Res2017;77:3834-45

[24] Wang Y,Kwiatkowski N.CDK7-dependent transcriptional addiction in triple-negative breast cancer.Cell2015;163:174-86 PMCID:PMC4583659

[25] Guarducci C,Russo D.Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor-positive breast cancer.Clin Cancer Res2024;30:1889-905 PMCID:PMC11061603

[26] Larochelle S,Terret ME.Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells.Mol Cell2007;25:839-50 PMCID:PMC1858677

[27] Zhang J,Zou C.Targeting super-enhancer-associated oncogenes in osteosarcoma with THZ2, a covalent CDK7 inhibitor.Clin Cancer Res2020;26:2681-92

[28] Feng M,Zhou W.The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma.J Exp Clin Cancer Res2023;42:44 PMCID:PMC9909925

[29] Zhang J,Li M.Targeted inhibition of KDM6 histone demethylases eradicates tumor-initiating cells via enhancer reprogramming in colorectal cancer.Theranostics2020;10:10016-30 PMCID:PMC7481431

[30] Chen Y,Huang M.MAFB promotes cancer stemness and tumorigenesis in osteosarcoma through a Sox9-mediated positive feedback loop.Cancer Res2020;80:2472-83

[31] Liu C,Chen X.Sox9 regulates self-renewal and tumorigenicity by promoting symmetrical cell division of cancer stem cells in hepatocellular carcinoma.Hepatology2016;64:117-29

[32] Adams JM,Castro EC.Sox9 is a modifier of the liver disease severity in a mouse model of alagille syndrome.Hepatology2020;71:1331-49 PMCID:PMC7048647

[33] Tang L,Xu K,Tang J.SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer.Oncogenesis2020;9:47 PMCID:PMC7217837

[34] Piao S,Rebecca VW.ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors in cancer cells.Autophagy2017;13:2056-71 PMCID:PMC5788553

[35] Akhtar MS,Tietjen JR.TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II.Mol Cell2009;34:387-93 PMCID:PMC2757088

[36] Drapkin R,Cho H,Reinberg D.Human cyclin-dependent kinase-activating kinase exists in three distinct complexes.Proc Natl Acad Sci U S A1996;93:6488-93 PMCID:PMC39050

[37] Lam FC,Wyckoff J.Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles.Nat Commun2018;9:1991 PMCID:PMC5959860

[38] Yan F,Li X.Hypoxia promotes non-small cell lung cancer cell stemness, migration, and invasion via promoting glycolysis by lactylation of SOX9.Cancer Biol Ther2024;25:2304161 PMCID:PMC10793688

[39] Han D,Zhao Y.Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs.J Clin Invest2024;134:e168649 PMCID:PMC11142739

[40] Zhou M,Huang G.Biomimetic nano-delivery of small-molecule piceatannol modulates tumor stemness and suppresses colorectal cancer metastasis via Hippo/YAP1/SOX9 signaling.Small2025;21:e2407191 PMCID:PMC11735875

[41] Han F,Li R.USP28 promotes PARP inhibitor resistance by enhancing SOX9-mediated DNA damage repair in ovarian cancer.Cell Death Dis2025;16:305 PMCID:PMC12003857

[42] Sun Y,Zhang Y.Serum lncRNA-ANRIL and SOX9 expression levels in glioma patients and their relationship with poor prognosis.World J Surg Oncol2021;19:287 PMCID:PMC8461887

[43] Chao M,Sun Z.TGF-β signaling promotes glioma progression through stabilizing Sox9.Front Immunol2020;11:592080 PMCID:PMC7886799

[44] Garros-Regulez L,Arrizabalaga O.mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.Expert Opin Ther Targets2016;20:393-405 PMCID:PMC4898154

[45] Xu X,Liu N.Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ.Int J Oncol2018;53:189-202

[46] Geng SL,Zhang X,Mi CL.Recombinant therapeutic proteins degradation and overcoming strategies in CHO cells.Appl Microbiol Biotechnol2024;108:182 PMCID:PMC10824870

[47] Liu M,Leng T,Xiong ZG.TRPM7 channels regulate glioma stem cell through STAT3 and Notch signaling pathways.Cell Signal2014;26:2773-81 PMCID:PMC4405379

[48] Pang Y,Zhao J.The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer.J Transl Med2022;20:336 PMCID:PMC9331486

[49] Chakraborty AK,Iqbal K.Lysine-specific demethylase 1 controls key OSCC preneoplasia inducer STAT3 through CDK7 phosphorylation during oncogenic progression and immunosuppression.Int J Oral Sci2025;17:31 PMCID:PMC12006301